
    
      This clinical study has two phases: prospective and retrospective.

      Prospective Phase - evaluates the post-market long-term effectiveness and safety of the
      Paragon CRT® 100 Contact Lenses, for temporary myopic refractive power reduction with minimum
      12-month period follow-up.

      Retrospective phase - evaluates the post-market long-term safety of the Paragon CRT® 100
      Contact Lenses, for temporary myopic refractive power reduction.
    
  